Literature DB >> 27138270

[Resection of advanced esophagogastric adenocarcinoma : Extended indications].

S P Mönig1,2, L M Schiffmann3.   

Abstract

In the current German S3 guidelines surgical treatment is not recommended for metastatic gastric cancer or metastatic adenocarcinoma of the esophagogastric junction; however, in routine practice the indications can be extended so that there may be occasions in which radical surgical intervention for specific individuals may be appropriate as part of a multimodal therapy with curative intent. This article presents the scientific rationale of such an approach based on the available literature considering modern, multimodal therapy concepts including criteria to be met for radical surgery. Currently only retrospective trials and limited current meta-analysis data are available for justifying surgical treatment for metastatic adenocarcinoma. The recently published initial results of the FLOT-3 study identified a patient subgroup that benefits from a resection even though metastasis has occurred. Whether surgical therapy will become an integral part of the treatment of limited metastatic adenocarcinoma of the stomach and esophagus in the future, has to be demonstrated by large prospective randomized studies, such as the RENAISSANCE/FLOT-5 study.

Entities:  

Keywords:  Adenocarcinoma esophagogastric junction; Gastric carcinoma; Guidelines; Metastasectomy; Metastasis

Mesh:

Year:  2016        PMID: 27138270     DOI: 10.1007/s00104-016-0183-4

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  14 in total

Review 1.  Non-curative gastric resection for patients with stage 4 gastric cancer--a single center experience and current review of literature.

Authors:  Yves Dittmar; Falk Rauchfuss; Max Goetz; Karin Jandt; Hubert Scheuerlein; Michael Heise; Utz Settmacher
Journal:  Langenbecks Arch Surg       Date:  2012-02-04       Impact factor: 3.445

2.  Significance of palliative gastrectomy for late-stage gastric cancer patients.

Authors:  Shi Chen; Yuan-Fang Li; Xing-Yu Feng; Zhi-Wei Zhou; Xiu-Hong Yuan; Ying-Bo Chen
Journal:  J Surg Oncol       Date:  2012-05-30       Impact factor: 3.454

3.  Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy.

Authors:  Olivier Glehen; François Noel Gilly; Catherine Arvieux; Eddy Cotte; Florent Boutitie; Baudouin Mansvelt; Jean Marc Bereder; Gérard Lorimier; François Quenet; Dominique Elias
Journal:  Ann Surg Oncol       Date:  2010-03-25       Impact factor: 5.344

Review 4.  The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review.

Authors:  Timothy L Fitzgerald; Jason Brinkley; Shannon Banks; Nasreen Vohra; Zachary P Englert; Emmanuel E Zervos
Journal:  Langenbecks Arch Surg       Date:  2014-08-23       Impact factor: 3.445

5.  Predictive factors improving survival after gastric and hepatic surgical treatment in gastric cancer patients with synchronous liver metastases.

Authors:  Jing Liu; Jing-Hui Li; Ru-Jun Zhai; Bo Wei; Ming-Zhe Shao; Lin Chen
Journal:  Chin Med J (Engl)       Date:  2012-01       Impact factor: 2.628

6.  Survival benefit of gastrectomy ± metastasectomy in patients with metastatic gastric cancer receiving chemotherapy.

Authors:  Ki Hwan Kim; Keun-Wook Lee; Sun Kyung Baek; Hye Jung Chang; Yu Jung Kim; Do Joong Park; Jee Hyun Kim; Hyung-Ho Kim; Jong Seok Lee
Journal:  Gastric Cancer       Date:  2011-03-04       Impact factor: 7.370

Review 7.  Metastatic gastric cancer (MGC) patients: Can we improve survival by metastasectomy? A systematic review and meta-analysis.

Authors:  Rahul Gadde; Leonardo Tamariz; Mena Hanna; Eli Avisar; Alan Livingstone; Dido Franceschi; Danny Yakoub
Journal:  J Surg Oncol       Date:  2015-06-12       Impact factor: 3.454

8.  Relationship between area of serosal invasion and intraperitoneal free cancer cells in patients with gastric cancer.

Authors:  M Ikeguchi; A Oka; S Tsujitani; M Maeta; N Kaibara
Journal:  Anticancer Res       Date:  1994 Sep-Oct       Impact factor: 2.480

9.  Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines.

Authors:  Jaffer A Ajani; David J Bentrem; Stephen Besh; Thomas A D'Amico; Prajnan Das; Crystal Denlinger; Marwan G Fakih; Charles S Fuchs; Hans Gerdes; Robert E Glasgow; James A Hayman; Wayne L Hofstetter; David H Ilson; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; A Craig Lockhart; Kenneth Meredith; Mary F Mulcahy; Mark B Orringer; James A Posey; Aaron R Sasson; Walter J Scott; Vivian E Strong; Thomas K Varghese; Graham Warren; Mary Kay Washington; Christopher Willett; Cameron D Wright; Nicole R McMillian; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2013-05-01       Impact factor: 11.908

10.  Value of palliative resection in gastric cancer.

Authors:  H H Hartgrink; H Putter; E Klein Kranenbarg; J J Bonenkamp; C J H van de Velde
Journal:  Br J Surg       Date:  2002-11       Impact factor: 6.939

View more
  3 in total

Review 1.  Gastric cancer treatment in the world: Germany.

Authors:  Seung-Hun Chon; Felix Berlth; Patrick Sven Plum; Till Herbold; Hakan Alakus; Robert Kleinert; Stefan Paul Moenig; Christiane Josephine Bruns; Arnulf Heinrich Hoelscher; Hans-Joachim Meyer
Journal:  Transl Gastroenterol Hepatol       Date:  2017-05-26

Review 2.  [Therapeutic approach in oligometastatic gastric and esophageal cancer].

Authors:  T Schmidt; S P Mönig
Journal:  Chirurg       Date:  2017-12       Impact factor: 0.955

Review 3.  [Oligometastases in gastric and esophageal cancer : Current clinical trials and surgical concepts].

Authors:  S Beckert; A Königsrainer
Journal:  Chirurg       Date:  2018-07       Impact factor: 0.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.